מדינה: קנדה
שפה: אנגלית
מקור: Health Canada
METHYLPREDNISOLONE ACETATE
PFIZER CANADA ULC
H02AB04
METHYLPREDNISOLONE
20MG
SUSPENSION
METHYLPREDNISOLONE ACETATE 20MG
INTRA-ARTICULAR
5ML
Prescription
ADRENALS
Active ingredient group (AIG) number: 0106292003; AHFS:
APPROVED
2003-10-03
DEPO-MEDROL (methylprednisolone acetate) - Product Monograph _ _ _Page 1 of 38_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR DEPO-MEDROL ® methylprednisolone acetate injectable suspension 20 mg/mL, 40 mg/mL, 80 mg/mL with Benzyl Alcohol injectable suspension, for intramuscular, intra- articular, intra-synovial and intralesional injection 40 mg/mL, 80 mg/mL with MGPC injectable suspension, for intramuscular, intra-articular, intra-synovial and intralesional injection USP Glucocorticoid Pfizer Canada ULC 17 300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Date of Initial Authorization: OCT 03, 2003 Date of Revision: MAR 15, 2024 Submission Control Number: 280641 ® TM Pfizer Enterprises, SARL Pfizer Canada ULC, Licensee © Pfizer Canada ULC, 2024 _ _ DEPO-MEDROL (methylprednisolone acetate) - Product Monograph _ _ _Page 2 of 38_ RECENT MAJOR LABEL CHANGES 4 DOSAGE AND ADMINISTRATION 03/2024 7 WARNINGS AND PRECAUTIONS, General and Endocrine and Metabolism 08/2023 8 ADVERSE REACTIONS 03/2024 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1. INDICATIONS ............................................................................................................... 4 1.1 Pediatrics ................................................................................................................ 6 1.2 Geriatrics ................................................................................................................ 6 2. CONTRAINDICATIONS ................................................................................................. 6 4 DOSAGE AND ADMINISTRATION .......... קרא את המסמך השלם